Navigation Links
In Pain Market, Huge Unmet Needs, Tough Regulatory Environment Challenge Pharmaceutical Companies, According to MedPredict

SCOTTSDALE, Ariz., June 23 /PRNewswire/ -- MedPredict has published a new report designed to provide critical strategic insight for pharma and biotech companies hoping to identify the next blockbuster drug for pain management. The report, entitled "Thought Leader Insight & Analysis: Pain/Analgesics," is based on in-depth interviews conducted with a panel of specialists in anesthesiology, psychiatry, rheumatology, gastroenterology and primary care.

The diagnosis and treatment of nociceptive, neuropathic and somatic pain varies considerably depending on the physician specialty. MedPredict's panelists in each specialty outline their therapeutic goals and unmet needs in treating pain associated with cancer, fibromyalgia, trauma, rheumatoid and osteoarthritis, back injury, neuropathy, depression, migraine and Crohn's disease.

"Pain is subjective," said Dr. Jeffrey Berk, MedPredict's president. "If you think that you hurt, you hurt. This subjectivity makes the diagnosis and treatment of pain exceedingly difficult, and it presents enormous challenges for researchers trying to demonstrate analgesic efficacy versus placebo." One path to success will be to narrowly define the population being studied, as Lilly has done with duloxatine in diabetic neuropathy, according to Dr. Berk.

MedPredict's panelists predict successes and failures in a number of therapeutic targets, including mu receptor agonists/opioids, serotonergic/noradrenergics, sodium and calcium channel blockers, NMDA/glutamate, Alpha-2 agonist, (mGlu2/3), acetylcholine, AMPA, cannabinoid, NF Kappa b, TRPV1/vanilloids, stimulants, NSAIDs, hyaluronic acid, anti-IL-10 and anti-IL-1. They evaluate the development pipeline based on the medical potential, mechanism of action, reimbursement and regulatory environment and relevance of Schedule II status.

Companies/Partnerships discussed in this report include Allergan, Allergan/Acadia, Alpharma, Alpharma/Institut Biochimique, Amgen, Amgen/Takeda, Anesiva, AstraZeneca, Avigen, BioDelivery Services, Cephalon, Endo, Forest, Forest/Cypress/Pierre Fabre, Forest/Lundbeck, GlaxoSmithKline, Grunenthal/Ortho-McNeil, Japan Tobacco, Johnson & Johnson, King/Acura, Lilly, Merck, NeurogesX, Novartis, Pfizer, Regeneron, UCB, Wyeth.

The full report can be purchased by contacting MedPredict.

About MedPredict

MedPredict ( maintains a proprietary database of over 1,000 global physician thought leaders, including 40+ specialties in 30+ therapeutic categories. Based on primary interviews with these thought leaders, MedPredict publishes periodic reports in each category to keep clients up-to-date on emerging trends and competitive activity. The reports include thought leader reactions to recent publications and medical conferences, as well as clinical, regulatory and marketing activity.

SOURCE MedPredict
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Having Penetrated Israels Domestic Telephony Market, 012 Smile.Communications Prepares for Its Next Goal: Entering Israels Cellular Market
2. CombiMatrix and Clarient Collaborate to Market, Sell Novel Genomics-Based Test for Chronic Lymphotic Leukemia (CLL)
3. Unmet Needs Provide Challenges and Opportunities for Rheumatoid Arthritis Drug Developers According to MedPredict Report
4. Biotech Avoids Fall Out From Tough Quarter for Capital Markets
5. Bringing a New Rhythm to Cardiology Workflow: Siemens Demonstrates Answers to Cardiologys Toughest Questions
6. pH Balanced RepHresh Vaginal Gel(R) now Available to Women in Canada Attacking Tough, Embarrassing Feminine Issues
7. Biotech Drops Amid Tough Markets in February
8. ATS Medical Announces Canadian Regulatory Approval of the ATS Open Pivot AP360 Mechanical Heart Valve
9. Neuftec Responds to a Fundamental Inaccuracy in Oxonica PLCs Regulatory Announcement
10. PAREXEL Product Development and Regulatory Experts to Attend the 2008 BIO International Convention
11. European Regulatory Agency Supports OPAXIO(TM) Brand Name for Cell Therapeutics Lung Cancer Drug
Post Your Comments:
(Date:11/26/2015)... , England , November 26, 2015 /PRNewswire/ ... Medical, an innovative medical device company specializing in imaging technologies, ... from the European Commission as part of the Horizon 2020 ... company to carry out a large-scale clinical trial in breast ...      (Logo: , --> ...
(Date:11/25/2015)... , November 25, 2015 2 ... première fois les différences entre les souches bactériennes ... celles des êtres humains . Ces recherches ... et envisager la prise en charge efficace de ... diagnostiqués chez les chats .    --> ...
(Date:11/25/2015)... DIEGO , Nov. 25, 2015  Neurocrine Biosciences, ... Kevin Gorman , President and CEO of Neurocrine Biosciences, ... Healthcare Conference in New York . ... to visit the website approximately 5 minutes prior to ... A replay of the presentation will be available on ...
(Date:11/25/2015)... DIEGO , Nov. 25, 2015 Orexigen® ... management will participate in a fireside chat discussion at ... New York . The discussion is scheduled ... .  A replay will be ... Media Contact:McDavid Stilwell  , Julie NormartVP, Corporate Communications ...
Breaking Biology Technology:
(Date:11/11/2015)... , Nov. 11, 2015   MedNet Solutions , ... spectrum of clinical research, is pleased to announce that it ... Clinical Trials (PCT) event, to be held November 17-19 ... able to view live demonstrations of iMedNet ... learn how iMedNet has been able to deliver ...
(Date:11/4/2015)... ALBANY, New York , November 4, 2015 /PRNewswire/ ... According to a new market report published by Transparency ... Size, Share, Growth, Trends and Forecast 2015 - 2022", ... value of US$ 30.3 bn by 2022. The market ... during the forecast period from 2015 to 2022. Rising ...
(Date:10/29/2015)... 2015  Rubicon Genomics, Inc., today announced an ... its DNA library preparation products, including the ThruPLEX ... Plasma-seq kit. ThruPLEX Plasma-seq has been optimized for ... libraries for liquid biopsies--the analysis of cell-free circulating ... in cancer and other conditions. Eurofins Scientific is ...
Breaking Biology News(10 mins):